Progress in small molecule therapeutics for the treatment of retinoblastoma

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 6, 2016, Pages 430-454

  Pritchard, Eleanor M ^a,b   Dyer, Michael A ^b,c,d   Guy, R Kiplin ^a  

^a Departments of Chemical Biology and Therapeutics   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Chemoreduction; Ocular drug delivery; Retinoblastoma

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BELINOSTAT; BETA LAPACHONE; BIOMATERIAL; CALCITRIOL; CARBOPLATIN; COMBRETASTATIN A4; ENTINOSTAT; ETOPOSIDE; FLUPHENAZINE; FOSTAMATINIB; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; MELPHALAN; NUTLIN 3; OUABAIN; PACLITAXEL; PROTEIN KINASE SYK INHIBITOR; PROTEIN MDMX; PROTEIN P53; ROMIDEPSIN; TOPOTECAN; TRICHOSTATIN A; UNINDEXED DRUG; VINCRISTINE; VITAMIN D DERIVATIVE; VORINOSTAT; IMIDAZOLE DERIVATIVE; MOLECULAR LIBRARY; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN MDM2; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SYK PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IC50; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RETINOBLASTOMA; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOKINETICS; PHARMACOLOGY; PROCEDURES; PROTEIN PROTEIN INTERACTION; RETINA; RETINAL NEOPLASMS; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PIPERAZINES; PROTEIN INTERACTION MAPS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA; SMALL MOLECULE LIBRARIES; SYK KINASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84961584035     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150722100610     Document Type: Article

References (188)

1. Federico, S.; Brennan, R.; Dyer, MA., Childhood Cancer and Developmental Biology: A Crucial Partnership. Curr. Top. Dev. Biol., 2011, 94, 1-13.
2. Chintagumpala, M.; Chevez-Barrios, P.; Paysse, E.A.; Plon, S.E.; Hurwitz, R. Retinoblastoma: Review of Current Management. Oncologist, 2007, 12, 1237-1246.
3. Shields, J.A.; Shields, C.L. Treatment of Retinoblastoma with Photocoagulation. Trans. Pa. Acad. Ophthalmol. Otolaryngol., 1990, 42, 951-954.
4. Shields, J.A.; Shields, C.L.; De Potter, P. Photocoagulation of Retinoblastoma. Intl. Opthalmol. Clin., 1993, 33, 95-99.
5. Shields, C.L.; Santos, C.M.; Diniz, W.; Gündüz, K.; Mercado, G.; Cater, J.R.; Shields, J.A. Thermotherapy for Retinoblastoma. Arch. Ophthalmol., 1999, 117, 885-893.
6. Abramson, D.H.; Ellsworth, R.M.; Rozakis, G.W. Cryotherapy for Retinoblastoma. Arch. Ophthalmol., 1982, 100, 1253-1256.
7. Shields, J.A.; Shields C.L. Treatment of Retinoblastoma with Cryotherapy. Trans. Pa. Acad. Ophthalmol. Otolaryngol., 1990, 42, 977-980.
8. Shah, N.V.; Houston, S.K.; Murray, T.G. Retinoblastoma and Treatment: A Current Evaluation of Advanced Therapy. World J. Pharmacol., 2013, 9, 65-72.
9. Shields, C.L.; Shields, J.A.; DePotter, P.; Minelli, S.; Hernandez, C.; Brady, L.W.; Cater, J.R. Plaque Radiotherapy in the Management of Retinoblastoma. Use as a Primary and Secondary Treatment. Ophthalmology, 1993, 100, 216-224.
10. Shields, C.L.; Shields, J.A.; Cater, J.; Othmane, I.; Singh, A.D.; Micaily, B. Plaque Radiotherapy for Retinoblastoma Long-term Tumor Control and Treatment Complications in 208 tumors. Ophthalmology, 2001, 108, 2116-2121.
11. Scott, I.U.; Murray, T.G.; Feuer, W.J.; Van Quill, K.; Markoe, A.M.; Ling, S.; Roth, D.B.; O’Brien, J.M. External Beam Radiotherapy in Retinoblastoma Tumor Control and Comparison of 2 Techniques. Arch Ophthalmol., 1999, 117, 766-770.
12. Munier, F.L.; Verwey, J.; Pica, A.; Balmer, A.; Zografos, L.; Abouzeid, H.; Timmerman, B.; Goitein, G.; Moeckli, R. New Developments in External Beam Radiotherapy for Fetinoblastoma: From Lens to Normal Tissue-Sparing Techniques. Clin. Exp. Ophthalmol., 2008, 36, 78-89.
13. Suzuki, S.; Kaneko, A. Management of Intraocular Retinoblastoma and Ocular Prognosis. Int. J. Clin. Oncol., 2004, 9, 1-6.
14. Shields, C.L.; Shields, J.A. Retinoblastoma Management: Advances in Enucleation, Intravenous Chemoreduction, and Intra-Arterial Chemotherapy. Curr. Opin. Ophthalmol., 2010, 21, 203-212.
15. Kim, J.W.; Abramson, D.H.; Dunkel, I.J. Current Management Strategies for Intraocular Retinoblastoma. Drugs, 2007, 67, 2173-2185.
16. Rodriguez-Galindo, C.; Chantada, G.L.; Haik, B.G.; Wilson, M.W. Treatment of Retinoblastoma: Current Status and Future Perspective. Curr. Treat. Options Neurol., 2007, 9, 194-207.
17. Shah, C.P.; Shields, C.L.; Shields, J.A. Chemotherapy for Malignant Intraocular Tumors. In: Retinal Pharmacotherapy; Nguyen, Q.D.; Rodrigues, E.B.; Farah, M.E.; Mieler, W.F., Eds.; Saunders Elsevier, 2010, pp 306-312.
18. Shields, C.L.; Fulco, E.M.; Arias, J.D.; Alarcon, C.; Pellegrini, M.; Rishi, P.; Kaliki, S.; Bianciotto, C.G.; Shields, J.A. Retinoblastoma Frontiers with Intravenous, Intra-Arterial, Periocular, and Intravitreal Chemotherapy. Eye, 2013, 27, 253-264.
19. Dyer, M.A.; Rodriguez-Galindo, C.; Wilson, M.W. Use of Preclinical Models to Improve Treatment of Retinoblastoma. PLoS Med., 2005, 2, e332.
20. Rodriguez-Galindo, C.; Wilson, M.W.; Haik, B.G.; Merchant, T.E.; Billups, C.A.; Shah, N.; Cain, A.; Langston, J.; Lipson, M.; Kun, L.E.; Pratt, C.B. Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin. J. Clin. Oncol., 2003, 21, 2019-2025.
21. Temming, P.; Lohmann, D.; Bornfeld, N.; Sauerwein, W.; Goericke, S.L.; Eggert, A. Current Concepts for Diagnosis and Treatment of Retinoblastoma in Germany: Aiming for Safe Tumor Control and Vision Preservation. Klin. Padiatr., 2012, 224, 339-347.
22. Rueegg, C.S.; Michel, G.; Wedenroth, L.; von der Weid, N.X.; Bergstraesser, E.; Kuehni, C.E.; Ammann, R. Physical Performance Limitations in Adolescent and Adult Survivors of Childhood Cancer and Their Siblings. PLoS One, 2012, 7, e47944.
23. Brinkman, T.M.; Merchant, T.E.; Li, Z.; Brennan, R.; Wilson, M.; Hoehn, M.E.; Qaddoumi, I.; Phipps, S.; Srivastava, D.; Robison, L.L.; Hudson, M.M.; Krull, K.R. Cognitive Function and Social Attainment in Adult Survivors of Retinoblastoma: A Report from the St. Jude Lifetime Cohort Study. Cancer, 2015, 121, 123-131.
24. Sachdeva, U.M.; O’Brien, J.M. Understanding pRb: Toward the Necessary Development of Targeted Treatments for Retinoblastoma. J. Clin. Invest., 2012, 122, 425-434.
25. Shiels, C.L.; Shields, J.A. Diagnosis and Management of Retinoblastoma. Cancer Control, 2004, 11, 317-327.
26. Murray, C.J.L.; Lopez, A.D. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020; Harvard University Press: Cambridge, 1996.
27. Nahum, M.P.; Gdal-On, M.; Kuten, A.; Herzl, G.; Horovitz, Y.; Weyl Ben Arush, M. Long-Term Follow-Up of Children with Retinoblastoma. Pediatr. Hematol. Oncol., 2001, 18, 173-179.
28. Hijiya, N.; Ness, K.K.; Ribeiro, R.C.; Hudson, M.M. Acute Leukemia as a Secondary Malignancy in Children and Adolescents: Current Findings and Issues. Cancer, 2009, 115, 23-35.
29. Rodriguez-Galindo, C. Second Malignancies and Other Long Term Effects in Retinoblastoma Survivors. In Retinoblastoma (pp. 115-126). Springer US, 2010.
30. Lin, H.Y.; Liao, S.L. Orbital Development in Survivors of Retinoblastoma Treated by Enucleation with Hydroxyapatite Implant. Br. J. Ophthalmol., 2011, 95, 630-633.
31. Zhang, J.; Benavente, C.A.; McEvoy, J.; Flores-Otero, J.; Ding, L.; Chen, X.; Ulyanov, A.; Wu, G.; Wilson, M.; Wang, J.; Brennan, R.; Rusch, M.; Manning, A.L.; Ma, J.; Easton, J.; Shurtleff, S.; Mullighan, C.; Pounds, S.; Mukatira, S.; Gupta, P.; Neale, G.; Zhao, D.; Lu, C.; Fulton, R.S.; Fulton, L.L.; Hong, X.; Dooling, D.J.; Ochoa, K.; Naeve, C.; Dyson, N.J.; Mardis, E.R.; Bahrami, A.; Ellison, D.; Wilson, R.K.; Downing, J.R.; Dyer, M.A. A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses. Nature, 2012, 481, 329-334.
32. Short, B.G. Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations. Toxicol. Pathol., 2008, 36, 49-62.
33. Jabbour, P.; Chalouhi, N.; Tjoumakaris, S.; Gonzalez, L.F.; Dumont, A.S.; Chitale, R.; Rosenwasser, R.; Bianciotto, C.G.; Shields, C. Pearls and Pitfalls of Intraarterial Chemotherapy for Retinoblastoma. J. Neurosurg. Pediatr., 2012, 10, 175-181.
34. Brennan, R.C.; Federico, S.; Bradley, C.; Zhang, J.; Flores-Otero, J.; Wilson M, Stewart, C.; Shu, F.; Guy, K.; Dyer, M.A. Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin- 3a. Cancer Res., 2011, 71, 4205-4213
35. Conway, R.M.; Wheeler, S.M., Murray, T.G.; Jockovich, M.E.; O’Brien, J.M. Retinoblastoma: Animal Models. Opthalmol. Clin. North Am., 2005, 18, 25-39
36. Nair, R.M.; Kaliki, S.; Vemuganti, G.K. Animal Models in Retinoblastoma Research. Saudi J. Opthalmol., 2013, 27, 141-146.
37. Zhang, K.; Zhang, L.; Weinreb, R.N. Ophthalmic Drug Discovery: Novel Targets and Mechanisms for Retinal Diseases and Glaucoma. Nat. Rev. Drug Discov., 2012, 11, 541-559.
38. Cunha-Vaz, J.G. The Blood-Retinal Barriers System. Basic Concepts and Clinical Evaluation. Exp. Eye Res., 2004, 78, 715-721.
39. Janoria, K.G.; Gunda, S.; Boddu, S.H.S.; Mitra, A.K. Novel Approaches to Retinal Drug Felivery. Exp. Opin. Drug Deliv., 2007, 4, 371-388.
40. Campbell, M.; Ozaki, E.; Humphries P. Systemic Delivery of Therapeutics to Neuronal Tissues: A Barrier Modulation Approach. Exp. Opin. Drug Deliv., 2010, 7, 859-869.
41. Sieg, J.W.; Robinson, J.R. Mechanistic Studies on Transcorneal Permeation of Pilocarpine. J. Pharm. Sci., 1976, 65, 1816-1822.
42. Duvvuri, S.; Majumdar, S.; Mitra, A.K. Drug Delivery to the Retina: Challenges and Opportunities. Expert Opin. Biol. Ther., 2003, 3, 45-56.
43. Anderson, O.A.; Bainbridge, J.W.B.; David T. Shima, D.T. Delivery of Anti-Angiogenic Molecular Therapies for Retinal Disease. Drug Discov. Today, 2010, 15, 272-282.
44. Urtti, A. Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery. Adv. Drug Dliv. Rev., 2006, 58, 1131-1135.
45. Thrimawithana, T.R.; Young, S.; Bunt, C.R.; Green, C.; Alany, R.G. Drug Delivery to the Posterior Segment of the Eye. Drug Discov. Today, 2011, 16, 270-277.
46. Shields, C.L.; Mashayekhi, A.; Au, A.K.; Czyz, C.; Leahey, A.; Meadows, A.T.; Shields, J.A. The International Classification of Retinoblastoma Predicts Chemoreduction Success. Opthalmology, 2006, 113, 2276-2280.
47. Berry, J.L.; Jubran, R.; Kim, J.W.; Wong, K.; Bababeygy, S.R.; Almarzouki, H.; Lee, T.C.; Murphree, A.L. Long-Term Outcomes of Group D eyes in Bilateral Retinoblastoma Patients Treated with Chemoreduction and Low-Dose IMRT Salvage. Pediatr. Blood Cancer, 2013, 60, 688-693.
48. Gündüz, K.; Günalp, I.; Yalçindag, N.; Unal, E.; Taçyildiz, N.; Erden, E.; Geyik, P.O. Causes of Chemoreduction Failure in Retinoblastoma and Analysis of Associated Factors Leading to Eventual Treatment with External Beam Radiotherapy and Enucleation. Opthalmology, 2004, 111, 1917-1924.
49. Shields, C.L.; Ramasubramanian, A.; Thangappan, A.; Hartzell, K.; Leahey, A.; Meadows, A.T.; Shields, J.A. Chemoreduction for Group E Retinoblastoma: Comparison of Chemoreduction Alone Versus Chemoreduction Plus Low-Dose External Radiotherapy in 76 eyes. Ophthalmology, 2009, 116, 544-551.
50. Sullivan, E.M.; Wilson, M.W.; Billups, C.A.; Wu, J.; Merchant, T.E.; Brennan, R.C.; Haik, B.G.; Shulkin, B.; Free, T.M.; Fiven, V.; Rodriguez-Galindo, C.; Qaddoumi, I. Pathologic Risk-Based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation. J. Pediatr. Hematol. Oncol., 2014, 36, e335-340.
51. Laurie, N.A.; Gray, J.K.; Zhang, J.; Leggas, M.; Relling, M.; Egorin, M.; Stewart, C.; Dyer, M.A. Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma. Clin. Cancer Res., 2005, 11, 7569-7578.
52. Nemeth, K.M.; Federico, S.; Carcaboso, A.M.; Shen, Y.; Schaiquevich, P.; Zhang, J.; Egorin, M.; Stewart, C.; Dyer, M.A. Subconjunctival Carboplatin and Systemic Topotecan Treatment in Preclinical Models of Retinoblastoma. Cancer, 2011, 117, 421-434.
53. Kaliki, S.; Shields, C.L.; Shah, S.U.; Eagle, R.C. Jr.; Shields, J.A.; Leahey, A. Postenucleation Adjuvant Chemotherapy with Vincristine, Etoposide and Carboplatin for the Treatment of High- Risk Retinoblastoma. Arch. Opthalmol., 2011, 129, 1422-1427.
54. Pritchard, E.M.; Stewart, E.; Zhu, F.; Bradley, C.; Griffiths, L.; Yang, L.; Suryadevara, P.K.; Zhang, J.; Freeman, B.; Guy, R.K.; Dyer, M.A. Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma. Pharm. Res., 2014, 11, 3060-3072.
55. Ericson, L.A.; Kalberg, B.; Rosengren, B.H. Trials of Intravitreal Injections of Chemotherapeutic Agents in Rabbits. Acta Ophthalmol., 1964, 42, 721-726.
56. Ueda, M.; Tanabe, J.; Inomata, M.; Kaneko, A.; Kimura, T. Study on Conservative Treatment of Retinoblastoma—Effect of Intravitreal Injection of Melphalan on the Rabbit Retina. Nippon Ganka Gakkai Zasshi, 1995, 99, 1230-1235.
57. Munier, F.; Gaillard, M.C.; Balmer, A.; Soliman, S.; Podlisky, G.; Moulin, A.P.; Beck-Popovic, M. Intravitreal Chemotherapy for Vitreous Disease in Retinoblastoma Revisited: From Prohibition to Conditional Indications. Br. J. Ophthalmol., 2012, 96, 1078-1083.
58. Kivelä, T.; Eskelin, S.; Paloheimo, M. Intravitreal Methotrexate for Retinoblastoma. Ophthalmology, 2011, 118, 1689.
59. Lad, E.M.; Moshfeghi, D.M. Minimizing the Risk of Endophthalmitis Following Intravitreal Injections. Compr. Ophthalmol. Update, 2006, 7, 277-286.
60. Jager, R.D.; Aiello, L.P.; Patel, S.C. Cunningham, E.T. Risks of Intravitreous Injection: A Comprehensive Review. Retina, 2004, 24, 676-698.
61. Smith S.J.; Smith, B.D. Evaluating the Risk of Extraocular Tumour Spread Following Intravitreal Injection Therapy for Retinoblastoma: A Systematic Review. Br. J. Opthalmol., 2013, 97, 1231-1236.
62. Abramson, D.H.; Dunkel, I.J.; Brodie, S.E.; Kim, J.W.; Gobin, Y.P. A Phase I/II Study of Direct Intra-Arterial (Ophthalmic Artery) Chemotherapy with Melphalan for Intraocular Retinoblastoma Initial Results. Ophthalmology, 2008, 115, 1398-1404.
63. Gobin, Y.P.; Dunkel, I.J.; Marr, B.P.; Brodie, S.E.; Abramson, D.H. Intra-Arterial Chemotherapy for the Management of Retinoblastoma: Four-Year Experience. Arch. Ophthalmol., 2011, 129, 732-737.
64. Muen, W.J.; Kingston, J.E.; Robertson, F.; Brew, S.; Sagoo, M.S.; Reddy, M.A. Efficacy and Complications of Super-Selective Intra- Ophthalmic Artery Melphalan for the Treatment of Refractory Retinoblastoma. Ophthalmology, 2012, 119, 611-616.
65. Patel, M.; Paulus, Y.M.; Gobin, Y.P.; Djaballah, H.; Marr, B.; Dunkel, I.J.; Brodie, S.; Antczak, C.; Folberg, R.; Abramson, D.H. Intra-Arterial and Oral Digoxin Therapy for Retinoblastoma. Opthalmic Genet., 2011, 32, 147-150.
66. Schaiquevich, P.; Buitrago, E.; Ceciliano, A.; Fandino, A.C.; Asprea, M.; Sierre, S.; Abramson, D.H.; Bramuglia, G.F.; Chantada, G.L. Pharmacokinetic Analysis of Topotecan after Superselective Ophthalmic Artery Infusion and Periocular Administration in a Porcine Model. Retina, 2012, 32, 287-395.
67. Marr, B.P.; Brodie, S.E.; Dunkel, I.J.; Gobin, Y.P.; Abramson, D.H. Three-Drug Intra-Arterial Chemotherapy Using Simultaneous Carboplatin, Topotecan and Melphalan for Intraocular Retinoblastoma: Preliminary Results. Br. J. Ophthalmol., 2012, 96, 1300-1303.
68. Venturi, C.; Bracco, S.; Cerase, A.; Cioni, S.; Galluzzi, P.; Gennari, P.; Vallone, I.M.; Tinturnin, R.; Vittori, C.; De Francesco, S.; Caini, M.; D’Ambrosio, A.; Toti, P.; Renieri, A.; Hadjistilianou, T. Superselective Ophthalmic Artery Infusion of Melphalan for Intraocular Retinoblastoma: Preliminary Results from 140 Treatments. Acta Ophthalmol., 2013, 91, 335-342.
69. Wilson M.W.; Jackson, J.S.; Phillips, B.X.; Buchanan, J.; Frase, S.; Wang, F.; Steinle, J.J.; Stewart, C.F.; Mandrell, T.D.; Haik, B.G.; Williams, J.S. Real-Time Ophthalmoscopic Findings of Superselective Intraophthalmic Artery Chemotherapy in a Nonhuman Primate Model. Arch. Ophthalmol., 2011, 129, 1458-1465.
70. Wilson, M.W.; Haik, B.G.; Dyer, M.A. Superselective Intraophthalmic Artery Chemotherapy. What We Do Not Know. Arch. Ophthalmol., 2011, 129, 1490-1491.
71. Munier, F.L.; Beck-Popovic, M.; Balmer, A.; Gaillard, M.C.; Bovey, E.; Binaghi, S. Occurrence of Sectoral Choroidal Occlusive Vasculopathy and Retinal Arteriolar Embolization after Superselective Ophthalmic Artery Chemotherapy for Advanced Intraocular Retinoblastoma. Retina, 2011, 31, 566-573.
72. Bianciotto, C.; Shields, C.L.; Iturralde J.C.; Sarici, A.; Jabbour, P.; Shields, J.A. Fluorescein Angiographic Findings after Intra-Arterial Chemotherapy for Retinoblastoma. Ophthalmology, 2012, 119, 843-849.
73. Steinle, J.J.; Zhang, Q.; Thompson, K.E.; Toutounchian, J.; Yates, C.R.; Soderland, C.; Wang, F.; Stewart, C.F.; Haik, B.G.; Williams, J.S.; Jackson, S.; Mandrell, T.D.; Johnson, D.; Wilson, M.W. Intra- Ophthalmic Artery Chemotherapy Triggers Vascular Toxicity through Endothelial Cell Inflammation and Leukostasis. Invest. Ophthalmol. Vis. Sci., 2012, 53, 2439-2445.
74. Geroski, D.H.; Edelhauser, H.F. Transscleral Drug Delivery for Posterior Segment Disease. Adv. Drug Dliv. Rev., 2001, 52, 37-48.
75. Simpson, A.E.; Gilbert, J.A.; Rudnick, D.E.; Geroski, D.H.; Aaberg, T.M. Jr.; Edelhauser, H.F. Transscleral Diffusion of Carboplatin: An In vitro and In vivo Study. Arch. Ophthalmol., 2002, 120, 1069-1074.
76. Martin, N.E.; Kim, J.W.; Abramson, D.H. Fibrin Sealant for Retinoblastoma: Where Are We? J. Ocul. Pharmacol. Ther., 2008, 24, 433-438.
77. Ambati, J.; Adamis, A.P. Transscleral Drug Delivery to the Retina and Choroid. Prog. Retin. Eye Res., 2002, 21, 145-151.
78. Mendelsohn, M.E.; Abramson, D.H.; Madden, T.; Tong, W.; Tran, H.T.; Dunkel, I.J. Intraocular Concentrations of Chemotherapy Following Systemic or Local Administration. Arch. Ophthalmol., 1998, 116, 1209-1212.
79. Hayden, B.C.; Jockovich, M.-E.; Murray, T.G.; Voigt, M.; Milne, P.; Kralinger, M.; Feuer, W.J.; Hernandez, E.; Parel, J.M. Pharmacokinetics of Systemic Versus Focal Carboplatin Chemotherapy in the Rabbit Eye: Possible Implication in the Treatment of Retinoblastoma. Invest. Ophthalmol. Vis. Sci., 2004, 45, 3644-3649.
80. Schmack, I.; Hubbard, G.B.; Kang, S.J.; Aaberg, T.M.; Grossniklau, H.E. Ischemic Necrosis and Atrophy of the Optic Nerve After Periocular Carboplatin Injection for Intraocular Retinoblastoma. Am. J. Ophthalmol., 2006, 142, 310-315.
81. Hayden, B.H.; Murray, T.G.; Scott, I.U.; Cicciarelli, N.; Hernandez, E.; Feuer, W.; Fulton, L.; O’Brien, J.M. Subconjunctival Carboplatin in Retinoblastoma: Impact of Tumor Burden and Dose Schedule. Arch. Ophthalmol., 2000, 118, 1549-1554.
82. Carcaboso, A.G.; Bramuglia, G.F.; Chantada, G.L.; Fandiño, A.C.; Chiappetta, D.A.; de Davila, M.T.G.; Rubio, M.C.; Abramson, D.H. Topotecan Vitreous Levels After Periocular or Intravenous Delivery in Rabbits: An Alternative for Retinoblastoma Chemotherapy. Invest. Ophthalmol. Vis. Sci., 2007, 48, 3761-3767.
83. Smith, S.J.; Pulido, J.S.; Salomão, D.R.; Smith, B.D.; Mohney, B. Combined Intravitreal and Subconjunctival Carboplatin for Retinoblastoma with Vitreous Seeds. Br. J. Opthalmol., 2012, 96, 1073-1077.
84. Chantada, G.L.; Fandiño, A.C.; Carcaboso, A.M.; Lagomarsino, E.; de Davila, M.T.G.; Guitter, M.R.; Rose, A.B.; Manzitti, J.; Bramuglia, G.F.; Abramson, D.H. A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma. Invest. Ophthalmol. Vis. Sci., 2009, 50, 1492-1496.
85. Schmack, I.; Hubbard, G.B.; Kang, S.J.; Aaberg, T.M. Jr.; Grossniklaus, H.E. Ischemic Necrosis and Atrophy of the Optic Nerve after Periocular Carboplatin Injection for Intraocular Retinoblastoma. Am. J. Ophthalmol., 2006, 142, 310-315.
86. Mulvihill, A.; Budning, A.; Jay, V.; Vandenhoven, C.; Heon, E.; Gallie, B.L.; Chan, H.S.L. Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma. Arch. Ophthalmol., 2003, 121, 1120-1124.
87. Abramson, D.H.; Frank, C.M.; Dunkel, I.J. A Phase I/II Study of Subconjunctival Carboplatin for Intraocular Retinoblastoma. Ophthalmology, 1998, 106, 1947-1950.
88. Kang, S.J.; Durairaj, C.; Kompella, U.B.; O’Brien, J.M.; Grossniklaus, H.E. Subconjunctival Nanoparticle Carboplatin in the Treatment of Murine Retinoblastoma. Arch. Ophthalmol., 2009, 127, 1043-1047.
89. Van Quill, K.R.; Dioguardi, P.K.; Tong, C.T.; Gilbert, J.A.; Aaberg, T.M.; Grossniklaus, H.E.; Edelhauser, H.F.; O’Brien, J.M. Subconjunctival Carboplatin in Fibrin Sealant in the Treatment of Transgenic Murine Retinoblastoma. Ophthalmology, 2005, 112, 1151-1158.
90. Tsui, J.Y.; Dalgard, C.; Van Quill, K.R.; Lee, L.; Grossniklau, H.E.; Edelhauser, H.F.; O’Brein, J.M. Subconjunctival Topotecan in Fibrin Sealant in the Treatment of Transgenic Murine Retinoblastoma. Invest. Opthalmol. Vis. Sci., 2008, 49, 490-496.
91. Mallipatna, A.C.; Dimaras, H.; Chan, H.S.L.; Héon, E.; Gallie, B.L. Periocular Topotecan for Intraocular Retinoblastoma. Arch. Ophthalmol., 2011, 129, 738-745.
92. Yousef, Y.A.; Halliday, W.; Chan, H.S.; Héon, E.; Gallie, B.L.; Dimaras, H. No Ocular Motility Complications after Subtenon Topotecan with Fibrin Sealant for Retinoblastoma. Can. J. Ophthalmol., 2013, 48, 524-528.
93. Gorodetsky, R.; Peylan-Ramu, N.; Reshef, A.; Gaberman, E.; Levdansky, L.; Marx, G. Interactions of Carboplatin with Fibrin(ogen), Implications for Local Slow Release Chemotherapy. J. Control Release, 2005, 102, 235-245.
94. Schouten van Meeteren, A.Y.N.; Moll, A.C.; Imhof, S.M.; Veerman, A.J.P. Chemotherapy for Retinoblastoma: an expanding area of clinical research. Med. Pediatr. Oncol., 2002, 38, 428-438.
95. Giuliano, M.; Lauricella, M.; Vassallo, E.; Carabilld, M.; Vento, R.; Tesoriere, G. Induction of apoptosis in human Retinoblastoma cells by topoisomerase inhibitors. Invest. Ophthalmol. Vis. Sci., 1998, 39, 1300-1311.
96. Nishimura, S.; Sato, T.; Ueda, H.; Ueda, K. Acute Myeloblastic Leukemia as a Second Malignancy in a Patient with Hereditary Retinoblastoma. J. Clin. Oncol., 2001, 19, 4182-4183.
97. Carcabosa, A.M., Chaippetta, D.A.; Opezzo, J.A.W.; Höcht, C.; Fandiño, A.C.; Croxatto, J.O.; Rubio, M.C.; Sosnik, A.; Abramson, D.H.; Bramuglia, G.F.; Chantada, G.L. Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. Invest. Ophthalmol. Vis. Sci., 2010, 51, 2126-2134.
98. Buitrago, E.; Höcht, C.; Chantaga, G.; Fandiño, A.; Navo, E.; Abramson, D.H.; Schaiquevich, P.; Bramuglia, G.F. Pharmacokinetic Analysis of Topotecan after Intra-Vitreal Injection: Implications for Retinoblastoma Treatment. Exp. Eye Res., 2010, 91, 9-14.
99. Frangoul, H.; Ames, M.M.; Mosher, R.B.; Reid, J.M.; Krailo, M.D.; Seibel, N.L.; Shaw, D.W.W.; Steinherz, P.G.; Whitlock, J.A.; Holcenberg, J.S. Phase I Study of Topotecan Administered as a 21-Day Continuous Infusion in Children with Recurrent Solid Tumors: A Report from the Children’s Cancer Group. Clin. Cancer Res., 1999, 5, 3956-3962.
100. Chantada, G.L.; Fandiño, A.C.; Casak, S.J.; Mato, G.; Manzitti, J.; Schvartzman, E. Activity of Topotecan in Retinoblastoma. Ophthalmic Genet., 2004, 25, 37-43.
101. Subramanian, N.; Raghunathan, V.; Kanwar, J.R.; Rupinder K. Kanwar, R.K.; Elchuri, S.V.; Khetan, V.; Krishnakumar, S. Target- Specific Delivery of Doxorubicin to Retinoblastoma using Epithelial Cell Adhesion Molecule Aptamer. Mol. Vis., 2012, 18, 2783-2795.
102. Kim, E.S.; Durairaj, C.; Kadam, R.S.; Lee, S.J.; Mo, Y.; Geroski, D.H.; Kompella, U.B.; Edelhauser H.F. Human Scleral Diffusion of Anticancer Drugs from Solution and Nanoparticle Formulation. Pharm. Res., 2009, 26, 1155-1161.
103. Chantada, G.L.; Fandiño, A.; Mato, G.; Casak, S. Phase II Window of Idarubicin in Children with Extraocular Retinoblastoma. J. Clin. Oncol., 1999, 17, 1847-1850.
104. Reid, J.; Pendergrass, T.; Krailo, M.; Hammond, G.D.; Ames, M.M. Plasma Pharmacokinetics and Cerebrospinal Fluid Concentrations of Idarubicin and Idarubicinol in Pediatric Leukemia Patients: A Children’s Cancer Study Group Report. Cancer Res., 1990, 50, 6525-6528.
105. Robert, J. Clinical Pharmacokinetics of Idarubicin. Clin. Pharmacokinet., 1993, 24, 275-288.
106. Ragab, A.H.; Sutow, W.W.; Komp, D.M.; Starling, K.A.; Lyon, G.M.; George, S. Adriamycin in the Treatment of Childhood Solid Tumors. Cancer, 1975, 36, 1572-1576.
107. Hu, T.; Le, Q.; Wu, Z.; Wu, W. Determination of Doxorubicin in Rabbit Ocular Tissues and Pharmacokinetics after Intravitreal Injection of a Single Dose of Doxorubicin-Loaded Poly-ß- hydroxybutyrate Microspheres. J. Pharm. Biomed. Anal., 2007, 43, 263-269.
108. Inomata, M.; Kanek, A. Chemosensitivity profiles of primary and cultured human Retinoblastoma cells in a human tumor clonogenic assay. Jpn. J. Cancer Res., 1987, 78, 858-868.
109. Shields, C.L.; Kaliki, S.; Shah, S.U.; Bianciotto, C.G.; Liu, D.; Jabbour, P.; Griffin, G.C.; Shields, J.A. Minimal Exposure (One or Two Cycles) of Intra-Arterial Chemotherapy in the Management of Retinoblastoma. Ophthalmology, 2012, 119, 188-192.
110. Ghassemi, F.; Shields, C.L. Intravitreal Melphalan for Refractory or Recurrent Vitreous Seeding from Retinoblastoma. Arch. Ophthalmol., 2012, 130, 1268-1271.
111. Shields, C.L.; Bianciotto, C.G.; Jabbour, P.; Griffin, G.C.; Ramasubramanian, A.; Rosenwasser, R.; Shields, J.A. Intra-Arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch. Ophthalmol., 2011, 129, 1407-1415.
112. Francis, J.H.; Schaiquevich, P.; Buitrago, E.; Del Sole, M.J.; Zapata, G.; Croxatto, J.O.; Marr, B.P.; Brodie, S.E.; Berra, A.; Chantada, G.L.; Abramson, D.H. Local and Systemic Toxicity of Intravitreal Melphalan for Vitreous Seeding in Retinoblastoma: A Preclinical and Clinical study. Ophthalmology, 2014, 121, 1810-1817.
113. Reid, T.W.; Albert, D.M.; Rabson, A.S.; Russell, P.; Craft, J.; Chu, E.W.; Tralka, T.S.; Wilcox, J.L. Characteristics of an Established Cell Line of Retinoblastoma. J. Nat. Cancer Inst., 1974, 53, 347-360.
114. McFall, R.C.; Sery, T.W.; Makadon, M. Characterization of a New Continuous Cell Line Derived from a Human Retinoblastoma. Cancer Res., 1977, 37, 1003-1010.
115. Griegel, S.; Hong, C.; Frotschl, R.; Hulser, D.F.; Greger, V.; Horsthemke, B.; Rajewsky, M.F. Newly Established Human Retinoblastoma Cell Lines Exhibit an “Immortalized” But Not an Invasive Phenotype In vitro. Int. J. Cancer, 1990, 46, 125-132.
116. Gallie, B.L.; Torgadis, J.; Han, L. Retinoblastoma In: Human Cell Culture Vol. II; Masters, J.R.W.; Palsson, B., Eds. Kluwer Academic Publishers: Great Britain, 1994, 361-374.
117. Lowes, D.; Pradhan, A.; Iyer, L.V.; Parman, T.; Gow, J.; Zhu, F.; Furimsky, A.; Lemoff, A.; Guiguemde, W.A.; Sigal, M.; Clark, J.A.; Wilson, E.; Tang, L.; Connelly, M.C.; DeRisi, J.L.; Kyle, D.E.; Mirsalis, J.; Guy, R.K. Lead Optimization of Antimalarial Propafenone Analogues. J. Med. Chem., 2012, 55, 6087-6093.
118. Dunn, K.C.; Aotaki-Keen, A.E.; Putkey, F.R.; Hjelmeland, L.M. ARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated Properties. Exp. Eye Res., 1996, 62,155-170.
119. Morales, M.-C.; Freire, V.; Asumendi, A.; Araiz, J.; Herrera, I.; Castiella, G.; Corcóstegui, I.; Corcóstegui, G. Comparative Effects of Six Intraocular Vital Dyes on Retinal Pigment Epithelial Cells. Invest. Ophthalmol. Vis. Sci., 2010, 51, 6018-6029.
120. Windle, J.J.; Albert, D.M.; O’Brien, J.M.; Marcus, D.M.; Disteche, C.M.; Bernards, R.A.; Mellon, P.L. Retinoblastoma in Transgenic Mice. Nature, 1990, 343, 665-669.
121. Mills MD, Windle JJ, Albert DM. Retinoblastoma in Transgenic Mice: Models of Hereditary Retinoblastoma. Surv. Ophthalmol., 1999, 43, 508-518.
122. Albert DM, Griep AE, Lambert PF, et al. Transgenic Models of Retinoblastoma: What They Tell Us About Its Cause and Treatment. Trans. Am. Ophthalmol. Soc., 1994, 92, 385-401.
123. Sabet, S.J.; Darjatmoko, S.R.; Lindstrom, M.J.; Albert, D.M. Antineoplastic Effect and Toxicity of 1,25-Dihydroxy-16-ene-23- yne-vitamin D3 in Athymic Mice with Y-79 Human Retinoblastoma Tumors. Arch. Ophthalmol., 1999, 117, 365-370.
124. Albert, D.M.; Kumar, A.; Strugnell, S.A.; Darjatmoko, S.R.; Lokken, J.M.; Lindstrom, M.J.; Patel, S. Effectiveness of Vitamin D Analogues in Treating Large Tumors and During Prolonged Use in Murine Retinoblastoma Models. Arch. Ophthalmol., 2004, 122, 1357-1362.
125. Kulkarni, A.D.; van Ginkel, P.R.; Darjatmoko, S.R.; Lindstrom, M.J.; Albert, D.M. Use of Combination Therapy with Cisplatin and Calcitriol in the Treatment of Y-79 Human Retinoblastoma Xenograft Model. Br. J. Ophthalmol., 2009, 93, 1105-1108.
126. Antczak, C.; Kloepping, C.; Radu, C.; Genski, T.; Müller-Kuhrt, L.; Siems, K.; de Stanchina, E.; Abramson, D.H.; Djaballah, H. Revisiting Old Drugs as Novel Agents for Retinoblastoma: In vitro and In vivo Antitumor Activity of Cardenolides. Invest. Ophthalmol. Vis. Sci., 2009, 50, 3065-3073.
127. Dyer, M.A.; Bremner, R. The Search for the Retinoblastoma Cell of Origin. Nat. Rev. Cancer, 2005, 5, 91-101.
128. Shih C-S, Laurie N, Holzmacher J, Hu Y, Nathwani AC, Davidoff AM, Dyer MA. AAV-Mediated Local Delivery of Interferon-ß for the Treatment of Retinoblastoma in Preclinical Models. Neuromol. Med., 2009, 11, 43-52.
129. Prassas, I.; Paliouras, M.; Datti, A.; Diamandis, E.P. High- Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of HumanTissue Kallikrein Expression: Implications for Cancer Therapies. Clin. Cancer. Res., 2008, 14, 5778-5784.
130. Prassas, I.; Dimandis, E.P. Novel Therapeutic Applications of Cardiac Glycosides. Nat. Rev. Drug Discov., 2008, 15, 926-935.
131. Zhang, H.; Qian, D.Z.; Tan, Y.S.; Lee, K.; Gao, P.; Ren, Y.R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.V.; Liu, J.O.; Semenza, G.L. Digoxin and Other Cardiac Glycosides Inhibit HIF- 1alpha Synthesis and Block Tumor Growth. Proc. Natl. Acad. Sci. USA, 2008, 105, 19579-19586.
132. Felth, J.; Rickardson, L.; Rosén, J.; Wickström, M.; Fryknäs, M.; Lindskog, M.; Bohlin, L.; Gulbo, J. Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs J. Nat. Prod., 2009, 72, 1969-1974.
133. Ekins, S.; Williams, A.J. Finding Promiscuous Old Drugs for New Uses. Pharm. Res., 2011, 28, 1785-1791.
134. Laurie, N.A.; Donovan, S.L.; Shih, C.-S.; Zhang, J.; Mills, N.; Fuller, C.; Teunisse, A.; Lam, S.; Ramos, Y.; Mohan, A.; Johnson, D.; Wilson, M.; Rodriguez-Galindo, C.; Quarto, M.; Francoz, S.; Medrysa, S.M.; Guy, R.K.; Marine, J.-C.; Hochemsen, A.G.; Dyer, M.A. Inactivation of the p53 Pathway in Retinoblastoma. Nature, 2006, 444, 61-66.
135. Elison, J.R.; Cobrinik, D.; Claros, N.; Abramson, D.H.; Lee, T.C.; Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells. Arch. Ophthalmol., 2006, 124, 1269-1275.
136. Zhang, F.; Tagen, M.; Throm, S.; Mallari, J.; Miller, L.; Guy, R.K.; Dyer, M.A.; Williams, R.T.; Roussel, M.F.; Nemeth, K.; Zhu, F.; Zhang, J.; Lu, M.; Panetta, J.C.; Boulos, N.; Stewart, C.F. Whole- Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. Drug Metab. Dispos., 2011, 39, 15-21.
137. Vassilev L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A.; In vivo Activation of the p53 Pathway by Small Molecule Antagonists of MDM2. Science, 2004, 303, 844-848.
138. Singh, R.; Masuda, E.S.; Payan, D.G. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors. J. Med. Chem., 2012, 55, 3614-3643.
139. Thoma, G.; Blanz, J.; Bühlmayer, P.; Drückes, P.; Kittelmann, M.; Smith, A.B.; van Eis, M.; Vangrevelinghe, E.; Zerwes, H.-G.; Che, J.; He, X.; Jin, Y.; Lee, C.C.; Michellys, P.-Y.; Uno, T.; Liu, H. Syk Inhibitors with High Potency in Presence of Blood. Bioorg. Med. Chem. Lett., 2014, 24, 2278-2282.
140. Currie, K.S.; Kropf, J.E.; Lee, T.; Blomgren, P.; Xu, J.; Zhao, Z.; Gallion, S.; Whitney, J.A.; Maclin, D.; Eric B., Lansdon, E.B.; Maciejewski, P.; Rossi, A.M.; Rong, H.; Macaluso, J.; Barbosa, J.; Di Paolo, J.A.; Mitchell, S.A. Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase. J. Med. Chem., 2014, 57, 3856-3873.
141. D’Cruz, O.J.; Uckun, F.M. Targeting Spleen Tyrosine Kinase (SYK) for Treatment of Human Disease. J. Pharm. Drug Dliv. Res., 2012,1, 2.
142. Gobessi, S.; Laurenti, L.; Longo, P.G.; Carsetti, L.; Berno, V.; Sica, S.; Leone, G.; Efremov, D.G. Inhibition of Constitutive and BCRinduced Syk Activation Downregulates Mcl-1 and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. Leukemia, 2009, 23, 686-697.
143. Baudot, A. D.; Jeandel, P.Y.; Mouska, X.; Maurer, U.; Tartare- Deckert, S.; Raynaud, S.D.; Cassuto, J.P.; Ticchioni, M.; Deckert, M. The Tyrosine Kinase Syk Regulates the Survival of Chronic Lymphocytic Leukemia B Cells Through PKCd and Proteasome- Dependent Regulation of Mcl-1 Expression. Oncogene, 2009, 28, 3261-3273.
144. Bodur, C.; Basaga, H. Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy. Curr. Med. Chem., 2012, 19, 1804-1820.
145. Azmi, A.S.; Wang, Z.; Philip, P.A.; Mohammad, R.M.; Sarkar, F.H. Emerging Bcl-2 Inhibitors for the Treatment of Cancer. Exp. Opin. Emerg. Drugs, 2011, 16, 59-70.
146. Falkenberg, K.J.; Johnstone, R.W. Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders. Nat. Rev. Drug Discov., 2014, 13, 673-691.
147. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E.T.; Yu, Q. Inhibitors of Histone Deacetylases Target the Rb-E2F1 Pathway for Apoptosis Induction Through Activation of Proapoptotic Protein Bim. Proc. Natl. Acad. Sci. USA, 2005, 102,16090-16095.
148. Dalgard, C.L.; Van Quill, K.R.; O’Brien, J.M. Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma. Clin. Cancer Res., 2008, 14, 3113-3123.
149. Pellegrini, F.; Budman, D.R. Review: Tubulin Function, Action of Antitubulin Drugs, and New Drug Development. Cancer Invest., 2005, 23, 264-273.
150. Nicolaou, K.C.; Guy, R.K.; Potier, P. Taxoids: New Weapons Against Cancer. Sci. Am., 1996, 274, 94-98
151. Yared, J.A.; Tkaczuk, K.H.R. Update on Taxane Development: New Analogs and New Formulations. Drug Des. Dev. Ther., 2012, 6, 371-384.
152. Di Fiore, R.; Drago-Ferrante, R.; D’Anneo, A.; Augello, G.; Carlis, D.; De Blasio, A.; Giuliana, M.; Tesoriere, G.; Vento, R. In Human Retinoblastoma Y79 cells Okadaic Acid-Parthenolide Co-treatment Induces Synergistic Apoptotic Effects, with PTEN as a Key Player. Cancer Biol. Ther., 2013, 14, 922-931.
153. Drago-Ferrante, R.; Santulli, A.; Di Fiore, R.; Giuliano, M.; Calvaruso, G.; Tesoriere, G.; Vento, R. Low Doses of Paclitaxel Potently Induce Apoptosis in Human Retinoblastoma Y79 Cells by up-regulating E2F1. Int. J. Oncol., 2008, 33, 677-687.
154. D'Anneo, A.; Augello, G.; Santulli, A.; Giuliano, M.; Di Fiore, R.; Messina, C.; Tesoriere, G.; Vento, R. Paclitaxel and Beta-Lapachone Synergistically Induce Apoptosis in Human Retinoblastoma Y79 Cells by Downregulating the Levels of Phospho-Akt. J. Cell Physiol., 2010, 222, 433-443.
155. Mitra, M.; Kandalam, M.; Sundaram, C. S.; Verma, R. S.; Maheswari, U.K.; Swaminathan, S.; Krishnakumar, S. Reversal of Stathmin-Mediated Microtubule Destabilization Sensitizes Retinoblastoma Cells to a Low Dose of Antimicrotubule Agents: A Novel Synergistic Therapeutic Intervention. Invest. Ophthalmol. Vis. Sci., 2011, 52, 5441-5448.
156. Suárez, F.; Jockovich, M. E.; Hernandez, E.; Feuer, W.; Parel, J. M.; Murray, T. G. Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma. Invest. Ophthalmol. Vis. Sci., 2007, 48, 3437-3440.
157. Kuwata, M.; Yoshizawa, K.; Matsumura, M.; Takahashi, K.; Tsubura, A. Ocular Toxicity Caused by Paclitaxel in Neonatal Sprague-Dawley Rats. In vivo, 2009, 23, 555-560.
158. Rowinsky, E. K.; Eisenhauer, E. A.; Chaudhry, V.; Arbuck, S. G.; Donehower, R. C. Clinical Toxicities Encountered with Paclitaxel (Taxol). Semin. Oncol., 1993, 20,1-15.
159. Deeb, K.K.; Trump, D.L.; Johnson, C.S. Vitamin D Signaling Pathways in Cancer: Potential for Anticancer Therapeutics. Nat. Rev. Cancer., 2007, 7, 684-700.
160. Audo, I.; Darjatmoko, S.R.; Schlamp, C.L.; Lokken, J.M.; Lindstrom, M.J.; Albert, D.M.; Nickells, R.W. Vitamin D Analogues Increase p53, p21, and Apoptosis in a Xenograft Model of Human Retinoblastoma. Invest. Ophthalmol. Vis. Sci., 2003, 44, 4192-4199.
161. Albert, D.M.; Nickella, R.W.; Gamm, D.M.; Zimbric, M.L.; Schlamp, C.L.; Lindstrom, M.J.; Audo, I. Vitamin D Analogs, a New Treatment for Retinoblastoma: The First Ellsworth Lecture. Ophthalmic Genet., 2002, 23, 137-156.
162. Wagner, N.; Wagner, K.D.; Schley, G.; Badiali, L.; Theres, H.; Scholz, H. 1,25-Dihydroxyvitamin D3-induced Apoptosis of Retinoblastoma Cells is Associated with Reciprocal Changes of Bcl-2 and bax. Exp. Eye Res., 2003, 77, 1-9.
163. Dormoy, V.; Béraud, C.; Lindner, V.; Coquard, C.; Barthelmebs, M.; Brasse, D.; Jacqmin, D.; Lang, H.; Massfelder, T. Vitamin D3 Triggers Antitumor Activity Through Targeting Hedgehog Signaling in Human Renal Cell Carcinoma. Carcinogenesis, 2012, 33, 2084-2093.
164. Tang, J.Y.; Xiao, T.Z.; Oda, Y.; Chang, K.S.; Shpall, E.; Wu, A.; So, P.-L.; Hebert, J.; Bikle, D.; Epstein, E.H. Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas. Cancer Prev. Res., 2011, 4, 744-751.
165. Albert, D.M.; Plum, L.A.; Yang, W.; Marcet, M.; Lindstrom, M.J.; Clagett-Dame, M.; DeLuca, H.F., Responsiveness of Human Retinoblastoma and Neuroblastoma Models to a Non-Calcemic 19- nor Vitamin D Analog. J. Ster. Biochem. Mol. Biol., 2005, 97, 165-172.
166. Folkman, J. Role of Angiogenesis in Tumor Growth and Metastasis. Semin. Oncol., 2002, 29, 15-18.
167. Lee, S.Y.; Kim, D.-K.; Cho, J.H.; Koh, J.-Y.; Yoon, Y.H. Inhibitory Effect of Bevacizumab on the Angiogenesis and Growth of Retinoblastoma. Arch. Ophthalmol., 2008, 126, 953-958.
168. Burnier, M.N.; McLean, I.W.; Zimmerman, L.E.; Rosenberg, S.H. Retinoblastoma: The Relationship of Proliferating Cells to Blood Vessels. Invest. Ophthalmol. Vis. Sci., 1990, 31, 2037-2040.
169. Escalona-Benz E, Jockovich M.-E., Murray T.G., Hayden B., Hernandez E, William Feuer W, Windle JJ. Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma. Invest. Ophthalmol. Vis. Sci., 2005, 46, 8-11.
170. Jockovich, M.E.; Murray, T.G.; Escalona-Benz, E.; Hernandez, E.; Feuer, W. Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LH BETATAG Mice. Invest. Ophthalmol. Vis. Sci., 2006, 47, 1264-1268.
171. Satish S. Kitambi, Kyle J. McCulloch, Randall T. Peterson, Jarema J. Malicki. Small Molecule Screen for compounds that affect vascular development in the zebrafish retina. Mechanisms of Development, 2009, 126, 464-477.
172. Albert, D.M.; Scheef, E.A.; Wang, S.; Mehraein, F.; Darjatmoko, S.R.; Christine M. Sorenson, C.M.; Sheibani, N. Calcitriol Is a Potent Inhibitor of Retinal Neovascularization. Invest. Ophthalmol. Vis. Sci., 2007, 48, 2327-2334.
173. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of Histologic Retinal Toxicity of Intravitreal Bevacizumab in a Rabbit Model. Am. J. Ophthalmol., 2006, 142, 162-164.
174. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing Intravitreal Toxicity of Bevacizumab (Avastin). Retina, 2006, 26, 257-261.
175. Miguel, N.C.; Matsuda, M.; Portes, A.L.; Allodi, S.; Mendez- Otero, R.; Puntar, T.; Sholl-Franco, A.; Krempel, P.G.; Monteiro M.L. In vitro effects of Bevacizumab Treatment on Newborn Rat Retinal Cell Proliferation, Death, and Differentiation. Invest. Ophthalmol. Vis. Sci., 2012, 53, 7904-7911.
176. Zayit-Soudry S, Zemel E, Barak A, Perlman I, Loewenstein A. Safety of intravitreal bevacizumab in the developing rabbit retina. Retina, 2011, 31, 1885-1895.
177. McEvoy, J.; Flores-Otero, J.; Zhang, J.; Nemeth, K.; Brennan, R.; Bradley, C.; Krafcik, F.; Rodriguez-Galindo, C.; Wilson, M.; Xiong, S.; Lozano, G.; Sage, J.; Louhibi, L.; Trimarchi, J.; Pani, A.; Smeyne, R.; Johnson, D.; Dyer, M.A. Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma Genesis. Cancer Cell, 2011, 20, 260-275.
178. Shen, Z.-X.; Chen, G.-Q.; Ni, J.-H.; Li, X.-S.; Xiong, S.-M.; Qui, Q.-Y.; Zhu, J.; Tang, W.; Sun, G.-L.; Yang, K.-Q.; Chen, Y.; Zhou, L.; Fang, Z.-W.; Wang, Y.-T.; Ma, J.; Zhang, P.; Zhang, T.-D.; Chen, S.-J.; Chen, Z.; Wang, Z.-Y. Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 1997, 89, 3354-3360.
179. Miller, W.H. Molecular Targets of Arsenic Trioxide in Malignant Cells. Oncologist, 2002, 7, 14-19.
180. Kim, J.H.; Kim, J.H.; Yu, Y.S.; Kim, D.H.; Kim, C.J.; Kim, K.-W. Antitumor Activity of Arsenic Trioxide on Retinoblastoma: Cell Differentiation and Apoptosis Depending on Arsenic Trioxide Concentration. Invest. Ophthalmol. Vis. Sci., 2009, 50, 1819-1823.
181. Nassr, M.; Wang, X.D.; Mitra, S.; Freeman-Anderson, N.E.; Patil, R.; Yates, R.; Miller, D.D.; Geisert, E.E. Treating Retinoblastoma in Tissue Culture and in a Rat Model with a Novel Isoquinoline Derivative. Invest. Ophthalmol. Vis. Sci., 2010, 51, 3813-3819.
182. Sareen, D.; van Ginkel, P.R.; Takach, J.C.; Mohiuddin, A.; Darjatmoko, S.R.; Albert, D.M.; Polans, A.S. Mitochondria as the Primary Target of Resveratrol-Induced Apoptosis in Human Retinoblastoma Cells. Invest. Ophthalmol. Vis. Sci., 2006, 47, 3708-3716.
183. Mahida, J.P.; Antczak, C.; DeCarlo, D.; Champ, K.G.; Francis, J.H.; Marr, B.; Polans, A.S.; Albert, D.M.; Abramson, D.H.; Djaballah, H. A Synergetic Screening Approach with Companion Effector for Combination Therapy: Application to Retinoblastoma. PLoS ONE, 2013, 8, e59156.
184. Thuyagarajan, S.; Thirumalai, K.; Nirmala, S.; Biswas, J.; Krishnakumar, S. Effect of Curcumin on Lung Resistance-Related Protein (LRP) in Retinoblastoma Cells. Curr. Eye Res., 2009, 34, 845-851.
185. Qu, Y.; Zhou, F.; Dai, X.; Wang, H; Shi, J.; Zhang, X.; Wang, Y.; Wei, W. Clinicopathologic Significances of Nuclear Expression of Nuclear Factor-?B Transcription Factors in Retinoblastoma. J. Clin. Pathol., 2011, 64, 695-700.
186. Mendelsohn, M.E.; Abramson, D.H.; Madden, T.; Tong, W.; Tran, H.T.; Dunkel, I.J. Intraocular Concentrations of Chemotherapeutic Agents After Systemic or Local Administration. Arch. Ophthalmol., 1998, 116, 1209-1212.
187. Carcaboso, A.M.; Chiappetta, D.A.; Opezzo, J.A.; Höcht, C.; Fandiño, A.C.; Croxatto, J.O.; Rubio, M.C.; Sosnik, A.; Abramson, D.H.; Bramuglia, G.F.; Chantada, G.L. Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. Invest. Ophthalmol. Vis. Sci., 2010, 54, 2126-2134.
188. Nalepa, G.; Rolfe, M.; Harpe, W. Drug Discovery in the Ubiquitin- Proteasome System. Nat. Rev. Drug Discov., 2006, 5, 496-613.